CAJ | 학술논문

结直肠癌（Colorectal cancer，CRC）是常见的消化系统恶性肿瘤，近几十年来其发病率和死亡率在全球范围内呈上升趋势。目前，在进展期结直肠癌的治疗中，化疗仍起重要作用，靶向治疗为患者带来新的希望，而且随着新一代化疗药物和靶向药物广泛应用于临床，患者生存质量得到了极大的改善，生存期得到了显著延长，靶向联合化疗也已成为转移性结直肠癌治疗研究热点之一。奥沙利铂＋卡培他滨（XELOX）作为一线化疗方案治疗转移性结直肠癌（mCRC）能取得很好的疗效，副作用轻，患者耐受良好；贝伐单抗作为一种新型靶向抗肿瘤药物，在抑制肿瘤组织生长和降低肿瘤细胞血行转移率方面显示出良好的效果。贝伐单抗联合XELOX方案治疗mCRC已被广泛研究报道，本文就对其疗效及安全性进行简要综述。
결직장암（Colorectal cancer，CRC）시상견적소화계통악성종류，근궤십년래기발병솔화사망솔재전구범위내정상승추세。목전，재진전기결직장암적치료중，화료잉기중요작용，파향치료위환자대래신적희망，이차수착신일대화료약물화파향약물엄범응용우림상，환자생존질량득도료겁대적개선，생존기득도료현저연장，파향연합화료야이성위전이성결직장암치료연구열점지일。오사리박＋잡배타빈（XELOX）작위일선화료방안치료전이성결직장암（mCRC）능취득흔호적료효，부작용경，환자내수량호；패벌단항작위일충신형파향항종류약물，재억제종류조직생장화강저종류세포혈행전이솔방면현시출량호적효과。패벌단항연합XELOX방안치료mCRC이피엄범연구보도，본문취대기료효급안전성진행간요종술。
Colorectal cancer is a common malignant tumor in digestive system ,with an increasing inci-dence rate and case fatality rate all over the world in recent decades .At present,chemotherapy still plays a very important role in the treatment of advanced colorectal cancer .Targeted therapy brings new hope to patients ,and new chemotherapy drugs and targeted drugs have been widely used in clinics .Patient′s life quality has been great-ly improved,survival time has been significantly prolonged ,the combination of chemotherapy and targeted therapy has also become a hot research area in the treatment of metastatic colorectal cancer .XELOX ( capecitabine plus oxaliplatin)as a first-line chemotherapy regimen in treating metastatic colorectal cancer (mCRC)can obtain good therapeutic effect ,the side effects of XELOX are light and well tolerated;Bevacizumab ,as a new type of targeted anti-tumor drugs ,shows a good effect in inhibiting tumor growth and reducing its hematogenous spread risk .Bev-acizumab in combination with XELOX regimen for treating mCRC has been widely investigated and reported .This review gives a brief summary on the efficacy and safety of the combined administration of Bevacizumab and XE -LOX.